Advertisement

Advertisement

mass screening

An Update on Cancer Screening in Older Adults

An Update on Cancer Screening in Older Adults

Members of the College of Family Physicians of Canada may claim one non-certified credit per hour for this non-certified educational program.

Mainpro+® Overview
Teaser: 

Shabbir M.H. Alibhai, MD, MSc, FRCP(C), Staff Physician, University Health Network, Toronto, ON, Canada, Assistant Professor, Departments of Medicine and Health Policy, Management, and Evaluation, University of Toronto, Research Scientist, Canadian Cancer Society

Abstract
More than one-half of new cancers and over 70% of cancer deaths occur in adults age 65 or older. Systematic screening has been associated with reductions in cancer- related mortality for a variety of cancers, including breast, cervical, and colorectal cancer. Prostate cancer screening remains more controversial despite the recent publication of two large randomized trials of screening. Although guidelines are beginning to address cancer screening specifically among the growing group of seniors age 70 or older, there is virtually no guidance on estimating remaining life expectancy or considering competing causes of mortality (e.g. comorbid medical illness) in this age group. In this article, I review evidence-based guidelines for cancer screening in adults and discuss the limitations of screening studies with respect to older adults. I have also highlighted new evidence and substantive updates to guidelines since the last publication on cancer screening in Geriatrics & Aging five years ago.

Keywords: cancer screening, aged, mass screening.

Screening for Early Dementia in Primary Care

Screening for Early Dementia in Primary Care

Teaser: 


Ellen Grober, PhD, Department of Neurology, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.

We have developed and validated a cost-effective case finding tool for early dementia in primary care that consists of two stages: a rapid dementia screening test administered to all patients over the age of 65 and a second stage to identify memory impairment administered to patients who fail the first stage. The Alzheimer’s Disease Screen for Primary Care (ADS-PC) had high sensitivity and specificity for early dementia and higher sensitivity for AD, and distinguished AD from non-AD dementias. The ADS-PC outperformed the MMSE and worked equally well in African-American and Caucasian primary care patients and in patients that differed in educational level.
Key words: Alzheimer’s disease, early dementia, mass screening, primary health care, neuropsychological tests.

Cancer Screening: Applying the Evidence to Adults beyond Age 70

Cancer Screening: Applying the Evidence to Adults beyond Age 70

Teaser: 


The accredited CME learning activity based on this article is offered under the auspices of the CE department of the University of Toronto. Participating physicians are entitled to one (1) MAINPRO-M1 credit by completing this program, found online at www.geriatricsandaging.ca/cme

Shabbir M.H. Alibhai, MD, MSc, FRCPC, Department of Medicine, University Health Network; Department of Medicine and Health Policy, Management, and Evaluation, University of Toronto, Toronto, ON.

More than one-half of new cancers and over 70% of cancer deaths in industrialized nations occur in adults age 65 or older. Systematic screening has been associated with reductions in cancer-related mortality for a variety of cancers, including breast, cervical, and colorectal cancer. While increasing numbers of older adults are living beyond 70, few guidelines address cancer screening in this group of older adults. In this article, evidence-based guidelines are reviewed for cancer screening in adults and limitations of screening studies with respect to older adults are discussed. A framework for deciding when to stop cancer screening in older adults is presented based on estimating remaining life expectancy, which incorporates age, comorbidity, and functional status.
Key words: cancer screening, aged, mass screening, overdiagnosis, cancer mortality.